Last reviewed · How we verify
NCT04100473: T2DM
Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus
Phase 2 trial testing Inhaled Human Insulin in Type 2 Diabetes Mellitus in 24 participants. Completed in 1 August 2019.
11 August 2018
Quick facts
| Lead sponsor | Dance Biopharm Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 23 April 2018 |
| Primary completion | 11 August 2018 |
| Estimated completion | 1 August 2019 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Inhaled Human Insulin — full drug profile →
- Insulin Lispro (Humalog U-100) — full drug profile →
Conditions studied
- Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Sponsor
Dance Biopharm Inc. — full company profile →
Who can join
Adults 18 to 75, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Developing Insulin Delivery Devices with Glucose Responsiveness.
Wang Z, Wang J, Kahkoska AR, Buse JB, et al · · 2021 · cited 22× · PMID 33250274 · DOI 10.1016/j.tips.2020.11.002
Verify or expand the search:
- PubMed search for NCT04100473
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes Mellitus
Currently open trials in the same condition.
- NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
- NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
- NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
- NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
- NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting
Other Dance Biopharm Inc. trials
Trials by the same sponsor.
- NCT03307512 — PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04100473 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dance Biopharm Inc.
- Last refreshed: 24 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04100473.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing